ATE238800T1 - Verwendung von squalamin zur herstellung eines arzneimittels zur inhibierung von nhe - Google Patents

Verwendung von squalamin zur herstellung eines arzneimittels zur inhibierung von nhe

Info

Publication number
ATE238800T1
ATE238800T1 AT96919096T AT96919096T ATE238800T1 AT E238800 T1 ATE238800 T1 AT E238800T1 AT 96919096 T AT96919096 T AT 96919096T AT 96919096 T AT96919096 T AT 96919096T AT E238800 T1 ATE238800 T1 AT E238800T1
Authority
AT
Austria
Prior art keywords
compounds
inhibitors
nhe
squalamine
drug
Prior art date
Application number
AT96919096T
Other languages
English (en)
Inventor
Michael Zasloff
Original Assignee
Genaera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaera Corp filed Critical Genaera Corp
Application granted granted Critical
Publication of ATE238800T1 publication Critical patent/ATE238800T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT96919096T 1995-06-07 1996-06-07 Verwendung von squalamin zur herstellung eines arzneimittels zur inhibierung von nhe ATE238800T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/474,799 US5792635A (en) 1995-06-07 1995-06-07 Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
PCT/US1996/008954 WO1996040151A1 (en) 1995-06-07 1996-06-07 Use of squalamine for the manufacture of a medicament for inhibiting nhe

Publications (1)

Publication Number Publication Date
ATE238800T1 true ATE238800T1 (de) 2003-05-15

Family

ID=23884982

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96919096T ATE238800T1 (de) 1995-06-07 1996-06-07 Verwendung von squalamin zur herstellung eines arzneimittels zur inhibierung von nhe

Country Status (12)

Country Link
US (1) US5792635A (de)
EP (1) EP0831837B1 (de)
JP (1) JP4077512B2 (de)
AT (1) ATE238800T1 (de)
AU (1) AU712436B2 (de)
CA (1) CA2223908C (de)
DE (1) DE69627853T2 (de)
DK (1) DK0831837T3 (de)
ES (1) ES2201187T3 (de)
PT (1) PT831837E (de)
WO (1) WO1996040151A1 (de)
ZA (1) ZA964819B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
ATE475365T1 (de) 1995-06-07 2010-08-15 Conceptus Inc Transzervikal einsetzbare empfängnisverhütungsvorrichtung zum verschluss der eileiter mit mechanischer befestigung am eileiter und einführsystem
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
PT910382E (pt) * 1996-04-26 2003-10-31 Genaera Corp Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
US7410959B1 (en) 2000-07-13 2008-08-12 Genaera Corporation Therapeutic uses for aminosterol compounds
WO1997044044A1 (en) * 1996-05-17 1997-11-27 Magainin Pharmaceuticals Inc. Therapeutic uses for an aminosterol compound
AU5194998A (en) * 1996-11-01 1998-05-29 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and uses therefor
US6262283B1 (en) 1996-12-06 2001-07-17 Magainin Pharmaceuticals Inc. Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
PL195897B1 (pl) * 1998-03-26 2007-11-30 Phytopharm Plc Zastosowanie smilageniny
DE19849722A1 (de) * 1998-10-28 2000-05-04 Aventis Pharma Gmbh Substituierte Phenyl-alkenoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
WO2001042273A2 (en) * 1999-12-09 2001-06-14 Genaera Corporation Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
DE19960204A1 (de) * 1999-12-14 2001-06-28 Aventis Pharma Gmbh Substituierte Norlbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DK1274718T3 (da) 2000-04-12 2007-02-12 Genaera Corp En fremgangsmåde til forberedelse af 7.alpha.-hydroxy 3-aminosubstituerede steroler vee en ubeskyttet 7.alpha.-hydroxy gruppe
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
ES2732251T3 (es) 2005-04-25 2019-11-21 Enterin Inc Dilactato de escualamina cristalino
MX2008013592A (es) * 2006-04-21 2009-03-06 Genaera Corp Induccion de perdida de peso e inhibicion selectiva de la proteina tirosina fosfatasa 1b.
WO2009032321A2 (en) * 2007-09-06 2009-03-12 Genaera Corporation A method for treating diabetes
US20120088737A2 (en) * 2009-10-02 2012-04-12 Ajinomoto Co., Inc Novel acyl guanidine derivatives
US8729058B2 (en) * 2009-10-27 2014-05-20 Michael Zasloff Methods and compositions for treating and preventing viral infections
WO2011066260A2 (en) * 2009-11-25 2011-06-03 Michael Zasloff Formulations comprising aminosterols
CA2848212C (en) 2011-09-08 2022-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MX367255B (es) * 2012-04-20 2019-08-12 Ohr Pharmaceutical Inc Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b (ptp1b).
PT2968369T (pt) * 2013-03-13 2018-12-05 Sage Therapeutics Inc Esteroides neuroativos e métodos para o seu uso
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3828194B1 (de) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterole und verfahren zur verwendung davon
HUE071964T2 (hu) 2015-07-06 2025-10-28 Sage Therapeutics Inc Oxiszterolok és alkalmazási eljárásaik
SMT202200300T1 (it) 2016-04-01 2022-09-14 Sage Therapeutics Inc Ossisteroli e relativi metodi d'uso
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2935057T3 (es) 2016-09-30 2023-03-01 Sage Therapeutics Inc C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
KR20230051723A (ko) 2016-10-18 2023-04-18 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
US11083735B2 (en) 2017-09-08 2021-08-10 Enterin, Inc. Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions
WO2021025974A1 (en) * 2019-08-02 2021-02-11 Enterin, Inc. Human squalamine derivatives, related compositions comprising the same, and methods of using the same
US12503485B2 (en) 2019-08-02 2025-12-23 Enterin, Inc. Human aminosterol ENT-03 compounds, related compositions comprising the same, and methods of using the same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3016390A (en) * 1960-06-30 1962-01-09 Searle & Co N-(substituted alkyl) amino-5alpha-androstan-17beta-ols
US3370070A (en) * 1965-06-16 1968-02-20 Searle & Co [n-alkyl-17-(dialkylaminoalkyl)amino] androst-4-en-3-ones
GB1565351A (en) * 1975-06-02 1980-04-16 Theramex Steroid aminoethers
US4220598A (en) * 1977-11-14 1980-09-02 Abbott Laboratories Method and reagents for measuring the level of conjugated bile acids
US4550163A (en) * 1979-02-05 1985-10-29 Abbott Laboratories Ligand analog-irreversible enzyme inhibitor conjugates
US4372888A (en) * 1980-08-26 1983-02-08 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Nondenaturing zwitterionic detergents
JPS5842878B2 (ja) * 1981-12-02 1983-09-22 名糖産業株式会社 １２−オキソコラン酸トシルヒドラゾン化合物、その製法ならびに利用
DE3366932D1 (en) * 1982-07-29 1986-11-20 Lehner Ag New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same
US5001116A (en) * 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4994443A (en) * 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
IT1221734B (it) * 1983-02-24 1990-07-12 Schiena Michele Giuseppe Di Ursodesossicolico solfato acido sale sodico
US4545938A (en) * 1983-11-02 1985-10-08 Beth Israel Medical Center Chemical synthesis
US4917826A (en) * 1985-10-18 1990-04-17 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
JPS62175497A (ja) * 1986-01-28 1987-08-01 Wakunaga Pharmaceut Co Ltd 胆汁酸誘導体およびその製造法
US5075464A (en) * 1987-04-22 1991-12-24 Merrell Dow Pharmaceuticals Inc. 17β-(cyclopropylamino)androstene derivatives
SE8702254D0 (sv) * 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
IT1229570B (it) * 1989-04-17 1991-09-04 Giuliani Spa Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
IT1229569B (it) * 1989-04-17 1991-09-04 Giuliani Spa Derivati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
JPH07116215B2 (ja) * 1989-04-19 1995-12-13 エスエス製薬株式会社 新規なステロイド化合物
PT93847A (pt) * 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
US4966897A (en) * 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US5004737A (en) * 1989-09-22 1991-04-02 Pacific Chemical Co., Ltd. Quaternary ammonium-substituted sterol derivatives
EP0466315A3 (en) * 1990-05-30 1992-07-01 Larrian Gillespie Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
DE69132048T2 (de) * 1990-06-11 2000-07-13 Alcon Laboratories Inc.(N.D.Ges.D.Staates Delaware), Forth Worth Verwendung von Steroiden zur Inhibierung von Angiogenesis
US5250524A (en) * 1990-12-06 1993-10-05 Hoechst Aktiengesellschaft Bile acid derivatives, process for their preparation and use of these compounds as pharmaceuticals
US5192756A (en) * 1992-03-18 1993-03-09 The Children's Hospital Of Pennsylvania Aminosterol antibiotic
EP0647133A4 (de) * 1992-06-12 1997-10-29 Affymax Tech Nv Zusammensetzungen und verfahren zur verbesserte arzneimittelabgabe.
AU6392894A (en) * 1993-02-26 1994-09-14 Magainin Pharmaceuticals, Inc. Chemical synthesis of squalamine
WO1994020520A1 (en) * 1993-03-10 1994-09-15 Magainin Pharmaceuticals Inc. Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants
ES2164110T3 (es) * 1994-03-10 2002-02-16 Magainin Pharma Usos farmaceuticos de derivados de esteroides.
AU723663C (en) * 1995-06-07 2001-11-01 Magainin Pharmaceuticals, Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds

Also Published As

Publication number Publication date
JPH11506775A (ja) 1999-06-15
ZA964819B (en) 1998-02-09
CA2223908A1 (en) 1996-12-19
AU712436B2 (en) 1999-11-04
AU6152896A (en) 1996-12-30
DK0831837T3 (da) 2003-08-25
EP0831837B1 (de) 2003-05-02
WO1996040151A1 (en) 1996-12-19
DE69627853D1 (de) 2003-06-05
US5792635A (en) 1998-08-11
ES2201187T3 (es) 2004-03-16
PT831837E (pt) 2003-09-30
DE69627853T2 (de) 2004-02-19
JP4077512B2 (ja) 2008-04-16
EP0831837A1 (de) 1998-04-01
CA2223908C (en) 2007-02-20

Similar Documents

Publication Publication Date Title
ATE238800T1 (de) Verwendung von squalamin zur herstellung eines arzneimittels zur inhibierung von nhe
WO1996040728A3 (en) Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (nhe), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the nhe-inhibitory efficacy of compounds
ES2193252T3 (es) Quinolonas y su uso terapeutico.
TR200001603T2 (tr) Yeni bileşikler
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
TR200101160T2 (tr) İkame edilmiş fenilusikloheksil bileşimlerinden elde edilmiş yeni esterler.
ES2067813T3 (es) Derivados substituidos de valinamida.
DE69329240D1 (de) 17-ether und thioether von 4-aza-steroiden
ES2186783T3 (es) Derivados de la dolastatina, su preparacion y uso.
ATE207929T1 (de) Diastereomerenreine 3-oxo und 3-thioxo-4-aza- androstanderivate und ihre verwendung als antiandrogene
DE69221563D1 (de) Polyfluoralkylthiopoly(ethylimidazolium)-Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als biozide Mittel
GR3025698T3 (en) NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES.
DK0696278T3 (da) Herbicidtvirkende substituerede 1-phenyl- eller 1-pyridinylbenzotriazoler
MX9700807A (es) Derivados de 3-azabiciclo (3.2.0)heptano n-sustituidos utiles como neurolepticos.
ATE155130T1 (de) Fluorverbindungen als aromatase-inhibitoren
DE59410304D1 (de) N-substituierte azabicycloheptan-derivate und ihre verwendung, z.b., als neuroleptika
TR199801659T2 (xx) Yeni triazolopurinler, haz�rlama y�ntemi, ila� olarak kullan�m�.
DE69502855D1 (de) (Pyrrolidinyl)phenylcarbamate und Zwischenverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente
NO870423D0 (no) 5-substituert octahydroindolizin-analgetika-forbindelser og 7-keto-mellomprodukt.
EP1067138A4 (de) Hydroxyprolin derivate
NO944722L (no) 3-(fenylalkylaminoalkyloksy)-5-fenylpyrazol-forbindelser samt fremgangsmåter og mellomprodukter for deres fremstilling, og legemidler som inneholder disse forbindelsene
NO305556B1 (no) Tiokarbamoylforbindelser og anvendelse derav samt middel for beskyttelse av tekniske materialer
DE69020520D1 (de) 2,19-Methylenoxy- und 2,19-methylenthiogebrückte Steroide und ihre Verwendung als Inhibitoren von Aromatase und 19-Hydroxylase.
ATE209493T1 (de) Verwendung von aspirochlorine oder dessen derivaten zur immunsuppression
ATE239015T1 (de) N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0831837

Country of ref document: EP

REN Ceased due to non-payment of the annual fee